Расширенный поиск

Гормональная терапия больных раком предстательной железы

Полный текст:

Об авторах

Б. Я. Алексеев
Московский научно-исследовательский онкологический институт им. П.А. Герцена

К. М. Нюшко
Московский научно-исследовательский онкологический институт им. П.А. Герцена

Список литературы

1. Чиссов В.И., Старинский В.В. Онкологическая заболеваемость в России в 2005 году. М.; 2007.

2. Catalona W.J., Richie J.P., Ahmann F.R. et al. Comparison of digital rectal examination an serum PSA in the early detection of prostate cancer. J Urol 1994;151(5):1283—90.

3. Catalona W.J., Smith D.S., Ratliff T.L., Basler I.W. Detection of organ-confined prostate cancer is increased through PSA-based screening. JAMA 1993;150(3):1018—23.

4. Catalona W.J., Smith D.S., Ratliff T.L. et al. Measurment of PSA in serum as screening test for prostate cancer. N Engl J Med 1991;324(17):1156—61.

5. Huggins C., Hoges C.V. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002;168(1):9—12.

6. Bayar D.P. Studies on prostate cancer and its treatment. 1977.

7. Daneshgari F., Crawford E.D., Endocrine therapy of advanced prostate cancer. Cancer 1993;71(3 Suppl):1089—97.

8. Kaisary A.V., Tyrrell C.J., Peeling W.B., Griffiths K. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502—8.

9. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360(9327):103—6.

10. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):937—46.

11. Messing E.M. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;170(5):1955; author reply 1955—6.

12. Quesnel M. Study on the administration of goserelin. Methodology and results. Soins 2007;(713):28—9.

13. Di Silverio F., Serio M. Zoladex in prostatic carcinoma. Drugs Exp Clin Res 1990;16 (Suppl):19—29.

14. Klarskov P., Lund F., Petersen S.E. Secondary treatment of advanced cancer of the prostate with Zoladex. Int Urol Nephrol 1990;22(4):359—62.

15. Di Silverio F., Serio M., D'Eramo G., Sciarra F. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 1990;18 (Suppl 3):54—61.

16. Boccardo F., Decensi A., Guarneri D. et al. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP). Eur Urol 1990;18 (Suppl 3):48—53.

17. Fourcade R.O., Cariou G., Coloby P. et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol 1990;18 (Suppl 3):45—7.

18. Iversen P. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA). Eur Urol 1990;18 (Suppl 3):41—4.

19. Denis L., Smith P.H., De Moura J.L. et al. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group. Eur Urol 1990;18 (Suppl 3):34—40.

20. Moffat L.E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18 (Suppl 3):26—7.

21. Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472—9.

22. Pilepich M.V., Winter K., Lawton C.A. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285—90.

23. Lawton C.A., Winter K., Grignon D., Pilepich M.V. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23(4):800—7.

24. Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972—8.

25. Zinner N.R., Bidair M., Centeno A., Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004;64(6):1177—81.

26. Fontana D., Mari M., Martinelli A. et al. 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int 2003;70(4):316—20.

27. Tsukagoshi S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)-out-line of pre-clinical and clinical studies. Gan To Kagaku Ryoho 2002;29(9): 1675—87.

28. Trueman J.A., Tillmann V., Cusick C.F. et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002;57(2):223—30.

29. Kotake T., Akaza H., Usami M. et al. Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer. Hinyokika Kiyo 2001;47(5):349—61.

30. Sarosdy M.F., Schellhammer P.F., Soloway M.S. et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999;83(7):801—6.

31. Fernandez del Moral P., Dijkman G.A., Debruyne F.M. et al. Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. Urology 1996;48(6):894—900.


Для цитирования:

Алексеев Б.Я., Нюшко К.М. Гормональная терапия больных раком предстательной железы. Онкоурология. 2007;3(3):57-62.

For citation:

Alekseyev B.Y., Nyushko K.M. Hormonal therapy for prostate cancer. Cancer Urology. 2007;3(3):57-62. (In Russ.)

Просмотров: 232

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)